Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer

@inproceedings{Henzler2016TruncationAC,
  title={Truncation and constitutive activation of the androgen receptor by diverse genomic rearrangements in prostate cancer},
  author={Christine M Henzler and Yingming Li and Rendong Yang and Terri McBride and Yeung Ho and Cynthia C. T. Sprenger and Gang Liu and Ilsa M. Coleman and Bryce Lakely and Rui Li and Shihong Ma and Sean R. Landman and V. Venkatesa Kumar and Tae Hyun Hwang and Ganesh V. Raj and Celestia S. Higano and Colm M Morrissey and Peter S. Nelson and Stephen R. Plymate and Scott M Dehm},
  booktitle={Nature communications},
  year={2016}
}
Molecularly targeted therapies for advanced prostate cancer include castration modalities that suppress ligand-dependent transcriptional activity of the androgen receptor (AR). However, persistent AR signalling undermines therapeutic efficacy and promotes progression to lethal castration-resistant prostate cancer (CRPC), even when patients are treated with potent second-generation AR-targeted therapies abiraterone and enzalutamide. Here we define diverse AR genomic structural rearrangements (AR… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 23 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 19 extracted citations

Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

The Journal of clinical investigation • 2017
View 20 Excerpts
Highly Influenced

Alternative splicing in prostate cancer

Nature Reviews Clinical Oncology • 2018

Similar Papers

Loading similar papers…